Teva Pharmaceutical Industries (TEVA) Other Non-Current Assets (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Other Non-Current Assets across 18 years of filings, most recently posting $1.8 billion for Q1 2026.

• Quarterly Other Non-Current Assets rose 286.64% year-over-year to $1.8 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 billion (up 286.64% YoY) and the FY2025 annual result came in at $405.0 million, down 77.13% from the prior year.
• Other Non-Current Assets climbed to $1.8 billion in Q1 2026, from $405.0 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $1.8 billion in Q3 2025 and troughed at $2.0 million in Q3 2024.
• A 5-year average of $544.4 million and a median of $450.0 million in 2023 frame the typical range for Other Non-Current Assets.
• Annual changes were most pronounced in 2022 — Other Non-Current Assets tumbled 98.06% — and 2025, when it jumped 90350.0%.
• Tracing TEVA's Other Non-Current Assets over 5 years: stood at $10.0 million in 2022, then surged by 4600.0% to $470.0 million in 2023, then surged by 276.81% to $1.8 billion in 2024, then slumped by 77.13% to $405.0 million in 2025, then surged by 342.96% to $1.8 billion in 2026.
• Business Quant data shows TEVA's Other Non-Current Assets at $1.8 billion in Q1 2026, $405.0 million in Q4 2025, and $1.8 billion in Q3 2025.